The stock of Moderna Inc (NASDAQ:MRNA) last traded at $103.46, down -2.86% from the previous session.
MRNA stock price is now 3.78% away from the 50-day moving average and 1.88% away from the 200-day moving average. The market capitalization of the company currently stands at $39.53B.
With the price target enhanced from $75 to $86, HSBC Securities Downgraded its rating from Hold to Reduce for Moderna Inc (NASDAQ: MRNA). On January 02, 2024, Oppenheimer Upgraded its previous ‘Perform’ rating to ‘Outperform’ on the stock keeping its target price maintained at $142, while ‘Canaccord Genuity’ rates the stock as ‘Hold’
In other news, Klinger Shannon Thyme, Chief Legal Officer sold 544 shares of the company’s stock on Mar 08 ’24. The stock was sold for $53,884 at an average price of $99.05. Upon completion of the transaction, the Chief Legal Officer now directly owns 9,267 shares in the company, valued at $0.96 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, President Hoge Stephen sold 309 shares of the business’s stock. A total of $29,151 was realized by selling the stock at an average price of $94.34. This leaves the insider owning 1,516,241 shares of the company worth $156.87 million. A total of 12.20% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $62.55 and a high of $163.24. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 3.42, and a quick ratio of 3.36. The fifty day moving average price for MRNA is $99.51 and a two-hundred day moving average price translates $101.44 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.55, beating analysts’ expectations of -$0.97 by 1.52. This compares to $3.74 EPS in the same period last year. The net profit margin was -68.76% and return on equity was -28.59% for MRNA. The company reported revenue of $2.81 billion for the quarter, compared to $5.08 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -44.71 percent. For the current quarter, analysts expect MRNA to generate $295.17M in revenue.
